News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer
Photo from sukruyazar.com
Jul 20, 2024, 10:37

Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer

Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post on X:

”ANTHER Trial Results: Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer. At a 10.3-year follow-up, dose-dense treatment showed:

  • Better recurrence-free survival (HR 0.80; P = 0.030). 
  • Better event-free survival (HR 0.78; P = 0.009). 
  • Improved distant disease-free survival (HR 0.79; P = 0.030).
  • There was no significant difference in overall survival (HR 0.82; P = 0.109).

Dose-dense regimens significantly improve breast cancer-free survival and disease-free survival compared to standard chemotherapy.”

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.

Authors: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis, Jonas Bergh.

Ivan R. Gonzalez

Source: Ivan R. Gonzalez/X

adjuvant chemotherapy Alexios Matikas Anne Andersson Breast Cancer cancer Günther G. Steger Hemming Johansson Iván R. González Jonas Bergh Mats Hellström Michael Gnant Michael Untch OncoDaily Oncology Per Malmström Richard Greil Sabine Schmatloch Sibylle Loibl Theodoros Foukakis Tommy Fornander Volker Möbus Yvonne Brandberg
Special Coverage
Insight
Nov 20, 2024, 20:44
Baris Turkbey: Excited to announce NCI Molecular Imaging members presenting their research at RSNA2024
Blog
Nov 20, 2024, 20:38
Franklin Iheanacho: Changing treatment patterns for hepatocellular carcinoma
Insight
Nov 20, 2024, 20:27
HIPEC improves overall survival in recurrent epithelial ovarian cancer
Blog
Nov 20, 2024, 19:12
Medicaid Cancer Foundation at 1Ummah Annual Convention
Insight
Nov 20, 2024, 19:12
Sahar Mansour: Advancing Breast Microcalcification Detection with AI
Blog
Nov 20, 2024, 19:12
Reflecting on Progress and Partnerships in Lung Cancer Care – Sarah Cannon Research Institute
Blog
Nov 20, 2024, 19:12
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC
Insight
Nov 20, 2024, 19:12
Nareg Varjabedian: Antidiabetic Drugs and Cancer Prevention
Insight
Nov 20, 2024, 19:12
Paolo Ciracì: Late-line options for patients with metastatic colorectal cancer
Insight
Nov 20, 2024, 19:12
Physicians’ perspectives on cancer-related fatigue management: A cross-sectional survey study in Germany - MASCC
Insight
Nov 20, 2024, 19:12
Ajay Major: Golcadomide and R-CHOP as first line for LBCL by Arnaud Amzallag et al.
Blog
Nov 20, 2024, 19:12
Rahul Gosain: Role of diet and exercise in cancer with Neil Iyengar